NEWSROOM

ODYY

Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II

Las Vegas, NV, Sept. 13, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the successful completion of safety measures for the second cohort of their Phase I Multi-Day Ascending Dosing (MAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects to determine drug safety. For...

read more

Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial

  Las Vegas, NV, August 18, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-enhancing medical products, today announced the successful completion of safety measures for their Phase I Multi-Day Ascending Dosing (MAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For MAD Cohort I, the drug was safe and well...

read more

Odyssey Health, Inc. Announces Positive Results from Its Phase I Multi-Day Ascending Dosing for the Treatment of Concussion

  Las Vegas, NV, August 10, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, a company focused on developing unique, life-improving medical products, today announces the completion and safety findings from Cohort I of its Multi-Day Ascending Dosing (MAD) arm for its Phase I Clinical Trial. Odyssey’s trial is administering PRV-002, its novel drug to treat concussion, to healthy human subjects. MAD Cohort I subjects were dosed for five...

read more

Odyssey Health, Inc. Launches New Corporate Website

  Las Vegas, NV, August 04, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, a company focused on developing unique, life-saving medical products, is pleased to announce the launch of its new innovative corporate website: https://www.odysseyhealthinc.com/. The new corporate website, like the Company’s previously announced name change, was designed to not only better reflect Odyssey Health’s mission and focus, but also improve communication...

read more

Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug

  Las Vegas, NV, July 12, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in their Phase I Single Ascending Dosing (SAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For SAD, the drug was safe and well tolerated. Concussions...

read more

Odyssey Health, Inc. Completes Safety Evaluation of Cohort II for Concussion Drug

  Las Vegas, NV, June 29, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, a company focused on developing unique, life-saving medical products, today announced positive safety findings from Cohort II of their Phase I clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. Data from Cohort II indicates that the drug was safe and well-tolerated. The trial is...

read more

RedChip Interviews Odyssey Health, Inc.’s CEO Michael Redmond

  Las Vegas, NV, June 08, 2022 -- McapMediaWire -- RedChip Companies will air a new C-Level interview with Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International on The RedChip Money Report® on Bloomberg TV, this Saturday, June 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the US. RedChip’s CEO Dave Gentry interviews Odyssey’s CEO Michael Redmond in this exclusive interview, covering the questions on the mind of...

read more

Odyssey Health, Inc. Completes Safety Evaluation of Cohort I for Concussion Drug

  IRVINE, CA, June 01, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, a company focused on developing unique, life-saving medical products, today announced positive safety findings from Cohort I of their Phase I clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For Cohort I, the drug was safe and well tolerated. Concussions represent an ‘unmet’ medical...

read more

Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug

  IRVINE, CA, May 5, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, a company focused on developing unique, life-saving medical products, today announced positive results from the first group of patients dosed with PRV-002, in their Phase I clinical trial. Odyssey’s trial is administering PRV-002, their novel drug to treat concussion, to healthy human subjects. Thus far the drug has shown to be safe and well tolerated. Each year, there...

read more

Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board

  IRVINE, CA, April 20, 2022 -- McapMediaWire -- Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing a proprietary drug compound to treat concussion, is honored to welcome Vice Admiral (r) Timothy Szymanski to the Company’s prestigious Military Advisory Board. Odyssey’s drug candidate, PRV-002 is currently in a phase 1 clinical trial. “Too many service members and veterans are suffering...

read more

Odyssey Group International Announces Formation of Military Advisory Board and Welcomes Prestigious Members to Assist with Concussion Drug Development

  IRVINE, CA, March 31, 2022 -- McapMediaWire -- Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced the formation of its Military Advisory Board with the appointment of prestigious leaders in the field. Garnering experience and insight from these leaders in our military service branches will provide critical insight to traumatic brain injuries and the effects it has on those...

read more

NFL LEGEND BRETT FAVRE AND ODYSSEY HEALTH, INC. INVOLVED WITH HUMAN TRIALS OF FIRST DRUG TREATMENT FOR CONCUSSION

    IRVINE, CA, Feb. 11, 2022 -- McapMediaWire -- Odyssey Health, Inc. f/k/a Odyssey Group International, Inc. (OTC Pink: ODYY) today announced the continued enrollment of its first in kind human clinical trial of its proprietary drug compound intended to treat concussion. NFL Hall of Fame Quarterback Brett Favre is one of the high-profile personalities having made headlines for his push to improve concussion treatments and protocols in the NFL, as well as other contact sports around...

read more

Odyssey Group International Receives Donation to Support a Treatment for Concussion and forms Community Partnership with the Erase PTSD Now Foundation

  IRVINE, CA, Jan. 10, 2022 -- McapMediaWire -- Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced that it has received a donation in the amount of $500,000 in partnership with the Erase PTSD Now organization and the Glenn Greenberg and Linda Vester Foundation. These funds will be used to progress the Phase 1 human clinical trials for drug candidate PRV-002 for the treatment...

read more

Categories

Mcap MediaWire - Costumer Service

Translate »